Neurocrine Gross Profit Margin from 2010 to 2024

NBIX Stock  USD 126.75  0.16  0.13%   
Neurocrine Biosciences Gross Profit Margin yearly trend continues to be fairly stable with very little volatility. Gross Profit Margin is likely to outpace its year average in 2024. During the period from 2010 to 2024, Neurocrine Biosciences Gross Profit Margin regression line of annual values had r-squared of  0.14 and arithmetic mean of  0.27. View All Fundamentals
 
Gross Profit Margin  
First Reported
2010-12-31
Previous Quarter
0.97896243
Current Value
1.03
Quarterly Volatility
1.36238255
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Neurocrine Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurocrine Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 22.4 M, Interest Expense of 7.4 M or Selling General Administrative of 894.2 M, as well as many indicators such as Price To Sales Ratio of 6.48, Dividend Yield of 0.0 or PTB Ratio of 6.13. Neurocrine financial statements analysis is a perfect complement when working with Neurocrine Biosciences Valuation or Volatility modules.
  
Check out the analysis of Neurocrine Biosciences Correlation against competitors.
For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.

Latest Neurocrine Biosciences' Gross Profit Margin Growth Pattern

Below is the plot of the Gross Profit Margin of Neurocrine Biosciences over the last few years. It is Neurocrine Biosciences' Gross Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurocrine Biosciences' overall financial position and show how it may be relating to other accounts over time.
Gross Profit Margin10 Years Trend
Slightly volatile
   Gross Profit Margin   
       Timeline  

Neurocrine Gross Profit Margin Regression Statistics

Arithmetic Mean0.27
Geometric Mean1.03
Coefficient Of Variation508.59
Mean Deviation1.01
Median0.98
Standard Deviation1.36
Sample Variance1.86
Range4.7797
R-Value0.37
Mean Square Error1.72
R-Squared0.14
Significance0.17
Slope0.11
Total Sum of Squares25.99

Neurocrine Gross Profit Margin History

2024 1.03
2022 0.98
2017 0.99
2016 -1.39
2014 -0.71
2013 -3.73

About Neurocrine Biosciences Financial Statements

Neurocrine Biosciences investors use historical fundamental indicators, such as Neurocrine Biosciences' Gross Profit Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Neurocrine Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Gross Profit Margin 0.98  1.03 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Neurocrine Stock Analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.